427 related articles for article (PubMed ID: 26461000)
21. Oncolytic immunovirotherapy for melanoma using vesicular stomatitis virus.
Diaz RM; Galivo F; Kottke T; Wongthida P; Qiao J; Thompson J; Valdes M; Barber G; Vile RG
Cancer Res; 2007 Mar; 67(6):2840-8. PubMed ID: 17363607
[TBL] [Abstract][Full Text] [Related]
22. Inhibitory Receptors Induced by VSV Viroimmunotherapy Are Not Necessarily Targets for Improving Treatment Efficacy.
Shim KG; Zaidi S; Thompson J; Kottke T; Evgin L; Rajani KR; Schuelke M; Driscoll CB; Huff A; Pulido JS; Vile RG
Mol Ther; 2017 Apr; 25(4):962-975. PubMed ID: 28237836
[TBL] [Abstract][Full Text] [Related]
23. Vesicular stomatitis virus-induced immune suppressor cells generate antagonism between intratumoral oncolytic virus and cyclophosphamide.
Willmon C; Diaz RM; Wongthida P; Galivo F; Kottke T; Thompson J; Albelda S; Harrington K; Melcher A; Vile R
Mol Ther; 2011 Jan; 19(1):140-9. PubMed ID: 20978474
[TBL] [Abstract][Full Text] [Related]
24. VSV oncolytic virotherapy in the B16 model depends upon intact MyD88 signaling.
Wongthida P; Diaz RM; Galivo F; Kottke T; Thompson J; Melcher A; Vile R
Mol Ther; 2011 Jan; 19(1):150-8. PubMed ID: 20959810
[TBL] [Abstract][Full Text] [Related]
25. Dendritic cells and T cells deliver oncolytic reovirus for tumour killing despite pre-existing anti-viral immunity.
Ilett EJ; Prestwich RJ; Kottke T; Errington F; Thompson JM; Harrington KJ; Pandha HS; Coffey M; Selby PJ; Vile RG; Melcher AA
Gene Ther; 2009 May; 16(5):689-99. PubMed ID: 19282847
[TBL] [Abstract][Full Text] [Related]
26. Radiation Attenuates Prostate Tumor Antiviral Responses to Vesicular Stomatitis Virus Containing IFNβ, Resulting in Pronounced Antitumor Systemic Immune Responses.
Udayakumar TS; Betancourt DM; Ahmad A; Tao W; Totiger TM; Patel M; Marples B; Barber G; Pollack A
Mol Cancer Res; 2020 Aug; 18(8):1232-1243. PubMed ID: 32366674
[TBL] [Abstract][Full Text] [Related]
27. A phase II randomized trial of Observation versus stereotactic ablative RadiatIon for OLigometastatic prostate CancEr (ORIOLE).
Radwan N; Phillips R; Ross A; Rowe SP; Gorin MA; Antonarakis ES; Deville C; Greco S; Denmeade S; Paller C; Song DY; Diehn M; Wang H; Carducci M; Pienta KJ; Pomper MG; DeWeese TL; Dicker A; Eisenberger M; Tran PT
BMC Cancer; 2017 Jun; 17(1):453. PubMed ID: 28662647
[TBL] [Abstract][Full Text] [Related]
28. Expression of IFN-beta enhances both efficacy and safety of oncolytic vesicular stomatitis virus for therapy of mesothelioma.
Willmon CL; Saloura V; Fridlender ZG; Wongthida P; Diaz RM; Thompson J; Kottke T; Federspiel M; Barber G; Albelda SM; Vile RG
Cancer Res; 2009 Oct; 69(19):7713-20. PubMed ID: 19773437
[TBL] [Abstract][Full Text] [Related]
29. Cost-Effectiveness Analysis of Stereotactic Ablative Radiation Therapy in Patients With Oligometastatic Cancer.
Kumar A; Straka C; Courtney PT; Vitzthum L; Riviere P; Murphy JD
Int J Radiat Oncol Biol Phys; 2021 Apr; 109(5):1185-1194. PubMed ID: 33002541
[TBL] [Abstract][Full Text] [Related]
30. Oncolytic Newcastle disease virus expressing a checkpoint inhibitor as a radioenhancing agent for murine melanoma.
Vijayakumar G; Palese P; Goff PH
EBioMedicine; 2019 Nov; 49():96-105. PubMed ID: 31676387
[TBL] [Abstract][Full Text] [Related]
31. Targeting Myeloid-derived Suppressor Cells and Programmed Death Ligand 1 Confers Therapeutic Advantage of Ablative Hypofractionated Radiation Therapy Compared With Conventional Fractionated Radiation Therapy.
Lan J; Li R; Yin LM; Deng L; Gui J; Chen BQ; Zhou L; Meng MB; Huang QR; Mo XM; Wei YQ; Lu B; Dicker A; Xue JX; Lu Y
Int J Radiat Oncol Biol Phys; 2018 May; 101(1):74-87. PubMed ID: 29619980
[TBL] [Abstract][Full Text] [Related]
32. Concurrent delivery of GM-CSF and B7-1 using an oncolytic adenovirus elicits potent antitumor effect.
Choi KJ; Kim JH; Lee YS; Kim J; Suh BS; Kim H; Cho S; Sohn JH; Kim GE; Yun CO
Gene Ther; 2006 Jul; 13(13):1010-20. PubMed ID: 16525479
[TBL] [Abstract][Full Text] [Related]
33. Virus specific tolerance enhanced efficacy of cancer immuno-virotherapy.
Sobhanimonfared F; Bamdad T; Sadigh ZA; Choobin H
Microb Pathog; 2020 Mar; 140():103957. PubMed ID: 31891795
[TBL] [Abstract][Full Text] [Related]
34. Engineering Newcastle Disease Virus as an Oncolytic Vector for Intratumoral Delivery of Immune Checkpoint Inhibitors and Immunocytokines.
Vijayakumar G; McCroskery S; Palese P
J Virol; 2020 Jan; 94(3):. PubMed ID: 31694938
[TBL] [Abstract][Full Text] [Related]
35. Intratumoral virotherapy with 4-1BBL armed modified vaccinia Ankara eradicates solid tumors and promotes protective immune memory.
Hinterberger M; Giessel R; Fiore G; Graebnitz F; Bathke B; Wennier S; Chaplin P; Melero I; Suter M; Lauterbach H; Berraondo P; Hochrein H; Medina-Echeverz J
J Immunother Cancer; 2021 Feb; 9(2):. PubMed ID: 33579736
[No Abstract] [Full Text] [Related]
36. Complete regression of advanced primary and metastatic mouse melanomas following combination chemoimmunotherapy.
Kohlmeyer J; Cron M; Landsberg J; Bald T; Renn M; Mikus S; Bondong S; Wikasari D; Gaffal E; Hartmann G; Tüting T
Cancer Res; 2009 Aug; 69(15):6265-74. PubMed ID: 19622767
[TBL] [Abstract][Full Text] [Related]
37. Oligometastatic non-small cell lung cancer: a narrative review of stereotactic ablative radiotherapy.
Dohopolski M; Iyengar P
Ann Palliat Med; 2021 May; 10(5):5944-5953. PubMed ID: 33691460
[TBL] [Abstract][Full Text] [Related]
38. Immunotherapy with tumor-targeted superantigens (TTS) in combination with docetaxel results in synergistic anti-tumor effects.
Sundstedt A; Celander M; Ohman MW; Forsberg G; Hedlund G
Int Immunopharmacol; 2009 Aug; 9(9):1063-70. PubMed ID: 19410661
[TBL] [Abstract][Full Text] [Related]
39. New concepts and insights into the role of radiation therapy in extracranial metastatic disease.
Ricardi U; Filippi AR; Franco P
Expert Rev Anticancer Ther; 2013 Oct; 13(10):1145-55. PubMed ID: 24134418
[TBL] [Abstract][Full Text] [Related]
40. Stereotactic ablative radiotherapy for the comprehensive treatment of 4-10 oligometastatic tumors (SABR-COMET-10): study protocol for a randomized phase III trial.
Palma DA; Olson R; Harrow S; Correa RJM; Schneiders F; Haasbeek CJA; Rodrigues GB; Lock M; Yaremko BP; Bauman GS; Ahmad B; Schellenberg D; Liu M; Gaede S; Laba J; Mulroy L; Senthi S; Louie AV; Swaminath A; Chalmers A; Warner A; Slotman BJ; de Gruijl TD; Allan A; Senan S
BMC Cancer; 2019 Aug; 19(1):816. PubMed ID: 31426760
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]